Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment

Scandinavian Journal of Immunology

Volumn 78, Issue 1, 2013, Pages 50-60

  Xu, W ^a   Cai, J ^b   Li, S ^a   Zhang, H ^b   Han, J ^b   Wen, M ^c   Wen, J ^b   Gao, F ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

^c HEBEI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2; PERFORIN; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE CELL TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL CYCLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOPHOSPHAMIDE; CYTOKINES; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84880251572     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12065     Document Type: Article

References (31)

1. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.
2. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93.
3. Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. Melanoma immunotherapy. Mt Sinai J Med 2010;77:620-42.
4. Hu ZW, Yang HZ. The pattern recognition receptor-mediated immune tolerance is involved in tumor metastasis. Sheng Li Ke Xue Jin Zhan 2010;41:5-10.
5. Motoyoshi Y, Kaminoda K, Saitoh O et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16:141-6.
6. Li J, Qian CN, Zeng YX. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009;9:590-2.
7. Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J 2010;16:342-7.
8. Nakagawa Y, Watari E, Shimizu M, Takahashi H. One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry. Biomed Res 2011;32:159-66.
9. Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001;61:6445-50.
10. Silke G, Michael S, Herbert R. Dendritic cells pulsed with tumor-derived lysateaugment T cell mediated tumor cell lysis. Otolaryngol Head Neck Surg 2004;131:176-7.
11. + T Iymphocyte eIicit responses. Blood 2000;96:1857-64.
12. Zhao WX, Yang JL, Li X, Ai J, Li T, Wang L. The quantitative detection of NKG2D, perforin and granzyme B gene expressions in lymphocytes by SYBR green I real-time fluorescence quantitative PCR. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010;26:1108-10.
13. Li YY, Yan CL. Inhibition of elicitation of allergic contact dermatitis by topical use of Z-VAD-FMK, a broad caspase inhibitor: experiment in mice. Zhonghua Yi Xue Za Zhi 2012;92:1992-6.
14. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8.
15. Kawakami Y. Cancer treatment by comprehensive regulation of anti-tumor immune network. Nihon Rinsho 2010;68:1094-9.
16. Labarriere N, Khammari A, Lang F, Dreno B. Is antigen specificity the key to efficient adoptive T-cell therapy? Immunotherapy 2011;3:495-505.
17. Jakóbisiak M, Gołab J. Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy. Arch Immunol Ther Exp (Warsz) 2010;58:347-54.
18. Liu JP, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta 2010;1805:35-42.
19. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008;7:370-5.
20. Bianchini R, Bistoni O, Alunno A et al. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Eur J Immunol 2011;41:2269-78.
21. Hazelrigg MR, Hirsch JI. Merchant RE. Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J Neurooncol 2002;60:143-50.
22. Skitzki J, Craig RA, Okuyama R et al. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 2004;64:2183-91.
23. Wu ZY, DU XH, Xu YX et al.Evaluation of in vivo labeled cytotoxic T lymphocytes and cytokine-induced killer cells migration and distribution of subcutaneous gastric tumor model in nude mice. Zhonghua Yi Xue Za Zhi 2010;90:403-6.
24. Ridolfi R, Riccobon A, Galassi R et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004;2:27.
25. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010;17:616-23.
26. Hassin D, Garber OG, Meiraz A, Schiffenbauer YS, Berke G. Cytotoxic T lymphocyte Perf and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology 2011;133:190-6.
27. Kim JH, Kang TH, Noh KH et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009;122:58-67.
28. Jenkins MR, Mintern J, La Gruta NL, Kedzierska K, Doherty PC, Turner SJ. Cell cycle-related acquisition of cytotoxic mediators defines the progressive differentiation to effector status for virus-specific CD8+ T cells. J Immunol 2008;181:3818-22.
29. Meslin F, Thiery J, Richon C, Jalil A, Chouaib S. GRZB-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells. J Biol Chem 2007;282:32991-9.
30. Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Focus on adoptive T Cell transfer trials in melanoma. Clin Dev Immunol 2010;2010:260-7.
31. Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010;120:1111-24.